---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-020093"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T07:03:00.100177+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Genprex signs exclusive license for diabetes gene therapy with University of Pittsburgh

## Summary
- Exclusive worldwide license for gene therapy using MafB promoter to drive Pdx1 and MafA for Type 1 and Type 2 diabetes.
- Preclinical NHP data showed statistically significant decreases in insulin requirements (p<0.001), increased c-peptide (p<0.05), improved glucose tolerance.
- Milestone payments up to ~$4.225M plus royalties; technology co-developed by Dr. George Gittes.
- Expands existing diabetes gene therapy portfolio; AAV vector delivered via endoscopy.

## SEC filing metadata
- accession: 0001437749-23-020093
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/0001437749-23-020093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/gnpx20230703_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-020093
- JSON: https://secwatch.observer/filing/0001437749-23-020093.json
- Plain text: https://secwatch.observer/filing/0001437749-23-020093.txt

## Key facts
- Material Agreements
  Genprex, Inc. entered into Exclusive License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at Initial license fee, annual maintenance fees, running low single digit royalties, minimum annual roy (effective 2023-07-14).
  - Action: entry
  - Agreement: license
  - Counterparty: University of Pittsburgh - Of the Commonwealth System of Higher Education
  - Value: Initial license fee, annual maintenance fees, running low single digit royalties, minimum annual roy
  - Effective: 2023-07-14
  source text: On July 14, 2023, Genprex, Inc. (“Genprex”) and the University of Pittsburgh - Of the Commonwealth System of Higher Education (“UP”) entered into an Exclusive License Agreement (the “UP License Agreement”), pursuant to which UP granted to Genprex a worldwide, exclusive license under certain patents and related technology, referred to collectively as the licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for both Type 1 and Type 2 diabetes using a MafB promoter to drive expression of the Pdx1 and MafA transcription factors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774923020093/0001437749-23-020093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.